Sucampo Pharmaceuticals Inactive 10-Q2013 Q1 Quarterly report

Filed: 10 May 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Abbreviated, absence, Adaptable, adecrease, agent, aim, Anchen, assigned, attributable, avoiding, BAG, began, beginningDecember, begun, big, Book, Bundesamt, Care, commitment, concomitantly, daily, Delaware, distribution, District, endedMarch, Excellence, fee, fixed, forlabel, formulation, Gesundheit, goalsalthough, governmental, history, IND, inflammatory, infringement, inspected, Institute, isUnited, JST, largest, lawsuit, LIBOR, light, loanagreement, longer, mcg, medicine, Mizuho, National, neurologic, nil, Notice, number, OM, Orange, organizationsto, paida, Par, passed, patent, pediatric, peptide, persuasive, pigmentosa, platform, prescription, project, pull, relocating, repayment, RP, Science, shift, solution, spray, TIBOR, Union, user, version, voluntary, wholesale

Removed: acquired, Administration, aggregated, arbitration, bona, called, central, Chamber, Commerce, description, enable, ending, entity, equipment, eye, fide, Food, funded, Healthcare, holdlicense, increased, leased, line, Master, meantime, MHRA, Monthly, municipal, NDA, negotiate, ongoing, ophthalmologic, orphan, planning, PMDAfor, position, prevailing, prostaglandin, reducing, reference, removal, rental, response, retain, submission, system, taxable, therapy, tiered, vascular

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Sucampo Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Sucampo Pharmaceuticals, Inc. (the “Company”) certifies to the best of his knowledge that:

(1)

The Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 of the Company (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2013	/s/ RYUJI UENO
	Ryuji Ueno, M.D., Ph.D., Ph.D.
	Chief Executive Officer
	(Principal Executive Officer)